
Delivery of Treatment for Haemophilia: Report of a Joint WHO/WFH/ISTH Meeting
Helps identify effective treatment strategies for hemophilia. Topics include delivery of treatment, on-demand treatment, prophylaxis, immune tolerance, and factor assays.
Year: 2025
Language: English
Author(s): World Federation of Hemophilia
Format: Video
The World Federation of Hemophilia invited representatives from its national member organizations, national governments, healthcare providers, industry partners, and other patient advocacy and scientific organizations from the global bleeding disorders community to an informational webinar on the recent milestone revisions to the World Health Organization (WHO) Essential Medicines List (EML). The objectives of this webinar were to provide information on these critical changes to WHO EML brining it more up-to-date with the international clinical guidelines for hemophilia and von Willebrand Disease, the advocacy carried out by the WFH in collaboration with key partners and stakeholders from the bleeding disorders community, and what does this mean in practice for our community. During the webinar participants heard from WFH President, Cesar Garrido, WFH Vice President Medical, Glenn Pierce, MD, PhD and Brian O’Mahony, Chief Executive, Irish Haemophilia Society, followed by a Q&A session.
Date recorded: October 17th, 2025.
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.

Helps identify effective treatment strategies for hemophilia. Topics include delivery of treatment, on-demand treatment, prophylaxis, immune tolerance, and factor assays.

The Hemophilia Treatment Centre (HTC) Twinning program pairs emerging HTCs with established ones to help increase the levels of diagnosis

A summary of discussions held at the World Federation of Hemophilia’s Global Forum on the Safety and Supply of Hemophilia

An overview of the issues surrounding the collection, manufacture, pricing, and marketing of factor replacement products.